The merger and asset sale represent a complete exit from the biotech business. Monitor the shareholder vote on the merger and the SEC effectiveness of the registration statement. The PIPE and the sale of MAT2203 provide some near-term cash, but the combined entity's future depends on GH Power's clean-energy business. The stock is likely to track the reverse-merger arbitrage spread until closing.
Price Chart
Executive Summary
Matinas BioPharma entered into a definitive business combination agreement with GH Power, a clean-energy company, in a reverse merger that will result in a change of control. Matinas shareholders will receive 0.1 Pubco common shares per share, and Matinas will sell its lipid nanocrystal platform and MAT2203 product candidate to Azurity Pharmaceuticals for $4M cash plus milestone and royalty payments. The transactions are interconditional and subject to shareholder and regulatory approvals, with an outside date of December 31, 2026.
Key Financial Metrics
Key Facts
- Matinas valued at ~$24.7M in the reverse merger with GH Power (valued at $250M); GH Power is a clean-energy/critical-minerals company.
- Matinas shareholders will receive 0.1 Pubco common shares for each share held; existing Matinas options and warrants will be assumed and converted into Pubco equivalents.
- GH Power is raising a PIPE of at least $15M concurrent with the closing.
- Matinas is selling its subsidiary holding the LNC platform and MAT2203 to Azurity Pharmaceuticals for $4M cash upfront plus up to $17.5M in milestones and low single-digit royalties on net sales.
- The sale of the biotech assets is conditioned on the closing of the merger, and the combined entity will be a clean-energy company, exiting the biotech business.
- Item 5.01 change in control: GH Power will control the post-closing Pubco board (4 of 5 directors) and management.
- Termination fee of $1M payable by Matinas to GH Power under certain circumstances.
Financial Impact
Matinas valued at ~$24.7M (based on the merger agreement); PIPE of at least $15M; asset sale for $4M cash plus up to $17.5M milestones and royalties.
Risk Factors
- Shareholder disapproval of the merger or the asset sale could derail the transactions.
- Regulatory or SEC delays in the registration statement (Form F-4) could push the closing beyond the December 31, 2026 outside date.
- The PIPE financing may not close or may be at less favorable terms.
- Asset sale to Azurity is contingent on the merger closing, creating a single point of failure.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 2 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-032938 |
| Exhibit: ex2-2.htm | 0001493152-26-032938 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 28, 2026 28d ago | 8-K | $2.53 $1.66 | ▼ −34.39% | ▼ −34.36% | $1.66 (−34.39%) |
Sep 16, 2026 5w ago | 8-K | $0.1630 $0.1613 | ▼ −1.02% | ▼ −2.23% | $1.66 (+918.40%) |
Sep 4, 2026 7w ago | 8-K | $0.1820 $3.01 | ▼ −1553.85% | ▼ −1552.13% | $1.66 (−812.09%) |
Aug 25, 2026 8w ago | 425 | $0.1973 $0.1750 | ▲ +11.30% | ▲ +12.28% | $1.66 (−741.36%) |
Jul 30, 2026 12w ago | 425 | $0.3174 $0.2000 | ▲ +36.99% | ▲ +40.95% | $1.66 (−423.00%) |
Jul 24, 2026 13w ago | 8-K | $0.3320 $0.1965 | ▲ +40.81% | ▲ +44.11% | $1.66 (−400.00%) |
Jul 13, 2026 15w ago | 425 | $0.4800 $0.2690 | ▲ +43.96% | ▲ +47.14% | $1.66 (−245.83%) |
Jul 13, 2026 15w ago | 8-K | $0.4800 $0.2690 | ▲ +43.96% | ▲ +47.14% | $1.66 (−245.83%) |
Jun 26, 2026 17w ago | 8-K | $0.6640 $0.2414 | ▲ +63.64% | ▲ +63.37% | $1.66 (−150.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers